To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
Age ≥18 years
Histologically diagnosed
Diffuse large B-cell lymphoma, not otherwise specified (NOS) or
High grade B-cell lymphoma (NOS or MYC and BCL2 rearrangements) or
Known central nervous system lymphoma or leptomeningeal disease
Adequately treated localized skin cancer without evidence of disease.
Adequately treated cervical carcinoma in situ without evidence of disease.
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, or put the study outcomes at undue risk.